BeiGene touts 'encouraging' response rates as the Chinese biotech mounts challenge to BTK, PD-1 leaders
As BeiGene sets the stage for a pivotal showdown with the OG BTK inhibitor Imbruvica, it’s zeroing in on a subset of patients for whom their drug, zanubrutinib, could be especially helpful.
The biotech — which has origins in China — also brandished the latest pivotal results for its PD-1 drug tislelizumab, another franchise shaker that’s under priority review in China, at the EHA Congress.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
